


# About rivaroxaban



By selectively binding to Factor Xa, rivaroxaban inhibits the conversion of prothrombin to thrombin

## How rivaroxaban works

Factor Xa has emerged as a target for new anticoagulants due to its pivotal role in the coagulation cascade where it stimulates the production of thrombin, the enzyme that promotes clot formation.<sup>1,2</sup> Factor Xa regulates thrombin generation, instead of inhibiting the action of thrombin, which may allow for other coagulation processes to continue.<sup>2</sup> Selective inhibition of Factor Xa is expected to help modulate the formation of the prothrombinase complex to reduce the so-called “thrombin burst.”<sup>2,3</sup>

## Clinical trial program

Janssen Research & Development, LLC and Bayer HealthCare are developing rivaroxaban jointly. The companies are evaluating rivaroxaban for a broad range of disorders in which blood clotting plays a major role. The extensive program of clinical trials evaluating rivaroxaban makes it the most studied oral, Factor Xa inhibitor in the world today.<sup>3</sup>

## FAST FACTS

- 1** Rivaroxaban is an oral anticoagulant being developed for a broad range of disorders in which blood clotting plays a major role.
- 2** Rivaroxaban is a Factor Xa inhibitor.<sup>1</sup> Factor Xa inhibitors influence thrombin generation rather than blocking the action of thrombin itself, potentially allowing for other coagulation processes to continue, such as wound healing following surgery.<sup>2</sup>
- 3** The extensive program of clinical trials evaluating rivaroxaban makes it the most studied oral, Factor Xa inhibitor in the world today.<sup>3</sup>
- 4** Janssen Research & Development, LLC and Bayer HealthCare are developing rivaroxaban jointly.

## References:

- Perzborn E, Straussburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor. *J Thromb Haemost.* 2005;3:514-521.
- Turpie AGG. Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. *Arterioscler Thromb Vasc Biol.* 2007;27(6):1238-1247.
- Lopes RD, Piccini JP, Hylek EM, et al. Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. *J Thromb Thrombolysis.* 2008;26:167-174.